Document is current

Any future updates will be listed below

712 SBT6290, a systemically administered Nectin-4-directed TLR8 ImmunoTAC (TM) therapeutic, is a potent human myeloid cell agonist for the treatment of Nectin-4-expressing tumors

Crossref DOI link: https://doi.org/10.1136/jitc-2020-SITC2020.0712

Published Online: 2020-11-09

Published Print: 2020-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark